Arno Therapeutics, Inc.
ARNI
$0.00
$0.000.00%
OTC PK
| 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | 09/30/2015 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.61M | 4.58M | 4.65M | 4.76M | 4.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.06M | 11.71M | 12.37M | 13.41M | 14.21M |
| Operating Income | -11.06M | -11.71M | -12.37M | -13.41M | -14.21M |
| Income Before Tax | -13.70M | -10.53M | -11.83M | -11.51M | -2.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.70 | -10.53 | -11.83 | -11.51 | -2.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.70M | -10.53M | -11.83M | -11.51M | -2.95M |
| EBIT | -11.06M | -11.71M | -12.37M | -13.41M | -14.21M |
| EBITDA | -11.06M | -11.70M | -12.37M | -13.40M | -14.20M |
| EPS Basic | -0.43 | -0.38 | -0.49 | -0.56 | -0.14 |
| Normalized Basic EPS | -0.27 | -0.24 | -0.31 | -0.35 | -0.08 |
| EPS Diluted | -0.43 | -0.38 | -0.49 | -0.56 | -0.19 |
| Normalized Diluted EPS | -0.27 | -0.24 | -0.31 | -0.35 | -0.11 |
| Average Basic Shares Outstanding | 145.45M | 121.15M | 100.00M | 81.63M | 81.63M |
| Average Diluted Shares Outstanding | 145.45M | 121.15M | 100.00M | 81.63M | 86.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |